8-K: GlucoTrack Implements 1-for-20 Reverse Stock Split and Announces Positive Results from First Human Clinical Study of Continuous Blood Glucose Monitor

GlucoTrack, Inc. announces a 1-for-20 reverse stock split and the successful completion of its first in-human clinical study for its continuous blood glucose monitor (CBGM).

Summary

• GlucoTrack, Inc. has implemented a 1-for-20 reverse stock split of its common stock, effective February 3, 2025.
• The reverse stock split reduced the number of outstanding shares from 155,491,473 to approximately 7,774,574.
• The company's common stock will trade on a split-adjusted basis starting February 4, 2025, with the ticker symbol remaining GCTK and a new CUSIP number of 45824Q705.
• GlucoTrack also announced the successful completion of its first in-human clinical study of its continuous blood glucose monitor (CBGM).
• The study focused on the safety and procedural aspects of the CBGM sensor lead placement, use, and removal.
• The study met its primary endpoint with no procedure or device related serious adverse events reported.
• The CBGM is designed as a long-term implantable device for three years of continuous, accurate blood glucose monitoring.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the successful clinical trial, but tempered by the reverse stock split and the need for future capital raises.

Positives

• The successful completion of the first in-human clinical study of the CBGM indicates potential for a new glucose monitoring solution.
• No serious adverse events were reported in the clinical study, suggesting the safety of the CBGM sensor lead placement, use, and removal.
• The CBGM is designed for long-term use (3 years) and has no on-body wearable component, offering a more convenient solution for patients.
• The study confirmed the function of the CBGM sensor lead in the subclavian vein.

Negatives

• The reverse stock split was likely done to increase the stock price to maintain Nasdaq listing requirements, which can be a sign of financial distress.
• The clinical study was a short-term in-hospital study over a period of four days, focusing on the safety and procedural aspects of the CBGM sensor lead placement, use, and removal, and did not evaluate sensor accuracy.

Risks

• GlucoTrack's ability to raise additional capital to finance its operations is a risk factor.
• The receipt and timing of regulatory approvals, including FDA approval, are uncertain.
• Risks related to enrollment of patients in, and the conduct of, clinical trials could impact the development timeline.
• The company's ability to hire and retain qualified personnel, including sales and distribution personnel, is a potential risk.

Future Outlook

The company plans to advance the CBGM technology into long-term clinical trials.

Management Comments

• 'We are thrilled with the results of this first in human clinical study, which establishes safety of the placement, usage and removal of the CBGM sensor lead,' said Paul V. Goode, PhD, President & Chief Executive Officer of Glucotrack.
• 'While neither the study nor prototype system was designed to evaluate sensor accuracy, the system performed as expected with similar accuracy results as previously seen in our animal studies,' said Paul V. Goode, PhD, President & Chief Executive Officer of Glucotrack.
• 'With these positive results, the promise of continuous blood glucose monitoring is one step closer to reality,' said Paul V. Goode, PhD, President & Chief Executive Officer of Glucotrack.

Industry Context

The announcement comes amid increasing demand for continuous glucose monitoring solutions in the diabetes management market, with companies like Dexcom and Abbott leading the space with their interstitial fluid-based CGM systems.

Comparison to Industry Standards

• Dexcom and Abbott's CGM systems measure glucose levels in interstitial fluid, while GlucoTrack's CBGM aims to directly measure blood glucose levels via an intravascular sensor.
• The three-year sensor longevity target of GlucoTrack's CBGM is significantly longer than the sensor life of current CGM systems like Dexcom's G7 and Abbott's FreeStyle Libre 3, which require sensor replacement every 10-14 days.
• Unlike existing CGM systems that have an on-body wearable component, GlucoTrack's CBGM is designed to be fully implantable, potentially offering a more convenient and less intrusive solution.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares owned due to the reverse stock split.
• Patients with diabetes may benefit from the development of a long-term implantable continuous blood glucose monitoring system.
• The successful clinical trial results may positively impact investor confidence.

Next Steps

• The company plans to advance the CBGM technology into long-term clinical trials.
• GlucoTrack will continue to develop and commercialize novel technologies for people with diabetes.

Key Dates

Keywords

continuous blood glucose monitor, reverse stock split, clinical study, glucose monitoring, Glucotrack, CBGM, diabetes